MindMed Advances 18-MC, Potential Treatment for Opioid Addiction, Into Further Clinical Testing

Posted by:

[ad_1]

18-MC is a proprietary, non-hallucinogenic molecule, based on the psychedelic ibogaine. In extensive nonclinical testing, 18-MC has shown promise …

[ad_2]

Source link

Continue Reading →
0
UA-77446339-1